Baxter Shakes Up Board: Two Directors Out, Ex-Biogen CFO McDonnell In
Baxter International Inc. (NYSE: BAX) announced significant changes to its board composition on February 12, 2026, with the appointment of former Biogen Chief Financial Officer Michael R. McDonnell as a new director and the simultaneous resignation of two long-serving board members, according to an SEC filing.
The Change
Michael R. McDonnell will join Baxter's Board of Directors effective February 13, 2026, and will immediately serve on the company's Audit Committee. His appointment coincides with the resignations of directors Cathy R. Smith and Stephen H. Rusckowski, both effective the same date. The dual departures will reduce Baxter's board size from twelve to ten directors.
McDonnell brings extensive financial leadership experience from the pharmaceutical and healthcare data analytics sectors. He most recently served as Executive Vice President and Chief Financial Officer of Biogen Inc. from August 2020 through February 2025, overseeing the biotechnology company's finances during a critical period of pipeline development and commercial transformation.
The departing directors leave notable gaps in board leadership. Smith had been serving on multiple committees, including chairing the Nominating, Corporate Governance & Public Policy Committee—a role that will immediately transfer to Patricia B. Morrison following the transition. According to the filing, neither Smith nor Rusckowski cited any disagreements with the company regarding operations, policies, or practices as reasons for their resignations.
Background
McDonnell's appointment represents a strategic addition of pharmaceutical industry expertise to Baxter's boardroom. His career spans over three decades in financial leadership, including a significant tenure as CFO of IQVIA Holdings Inc. (formerly Quintiles IMS) from December 2015 through July 2020, where he helped guide the world's largest healthcare data analytics company through significant growth and transformation.
Prior to his healthcare sector roles, McDonnell accumulated diverse financial leadership experience across multiple industries. He served as CFO of Intelsat S.A. from 2008 to 2015, navigating the satellite communications company through complex capital structures. Earlier in his career, he held CFO positions at MCG Capital Corporation and EchoStar Communications Corporation (now DISH Network), and spent 14 years at PricewaterhouseCoopers LLP, including four years as a partner.
Baxter, a global medical products company with a focus on critical care, nutrition, renal care, and hospital products, has faced ongoing challenges in recent years. The company's recent earnings release, also disclosed in the February 12 filing, coincided with the declaration of a modest quarterly dividend of $0.01 per share, payable April 1, 2026.
What It Means
The board refresh signals potential strategic recalibration at Baxter as it navigates an evolving healthcare landscape. McDonnell's deep financial expertise and recent experience at Biogen—a company known for its focus on neurological and neurodegenerative diseases—could prove valuable as Baxter seeks to optimize its portfolio and improve operational efficiency.
His appointment to the Audit Committee leverages his extensive financial reporting background, particularly crucial given his experience overseeing finances at complex, highly regulated pharmaceutical companies. This expertise may be particularly relevant as Baxter continues to manage its diverse business segments and evaluate strategic options.
The simultaneous departure of two directors and immediate reduction in board size suggests a deliberate streamlining of governance structure. While the company provided no specific rationale for the resignations, the timing alongside McDonnell's appointment indicates coordinated succession planning rather than unexpected departures.
McDonnell will receive compensation consistent with Baxter's standard non-employee director compensation plan, including prorated equity awards for his 2026 service period. He currently serves on the board of Merit Medical Systems, Inc., adding to his governance experience in the medical device sector.
The leadership transition comes at a pivotal time for Baxter as the medical products industry continues to face supply chain pressures, pricing challenges, and evolving regulatory requirements. McDonnell's cross-industry financial leadership experience, combined with his recent immersion in the biopharmaceutical sector, positions him to provide valuable perspective as Baxter charts its path forward.
*Source: Baxter International Inc. Form 8-K filed with the SEC on February 12, 2026*
*StockCliff Research*